Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s Ascletis Pharma (HKEX: 1672).
Top-line results from its USA-based trial of ASC30 show the tablet was well tolerated, with dose-proportional pharmacokinetic properties and a long half-life of up to 60 hours.
While it is still early days, the data have the potential to excite, given that ASC30 would be the first and only small molecule GLP-1R agonist that can be dosed monthly subcutaneously and once daily orally for the treatment of obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze